GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Authors
Keywords
GLP-1 receptor agonist, Type 2 diabetes mellitus, Cardiovascular outcomes
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 32, Issue 1, Pages 65-72
Publisher
Springer Nature
Online
2018-02-14
DOI
10.1007/s10557-018-6773-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials
- (2017) Yochai Birnbaum et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
- (2016) Łukasz Bułdak et al. Pharmacological Reports
- Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation
- (2015) Yue Zhou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart
- (2015) Li-Hui Zhang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
- (2015) A.J. Scheen et al. DIABETES & METABOLISM
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
- (2015) Annachiara Uccellatore et al. Diabetes Therapy
- Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
- (2015) Annachiara Uccellatore et al. Diabetes Therapy
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways
- (2015) Kosuke Nagayama et al. PLoS One
- GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A
- (2014) Yao Dai et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury
- (2014) Alyssa H. Yoon et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a
- (2013) Craig W. Younce et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation
- (2013) K Pabreja et al. BRITISH JOURNAL OF PHARMACOLOGY
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes
- (2013) Susan Herzlinger et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – preclinical evidence
- (2013) Ulrich Werner JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
- (2012) Ayako Ojima et al. AMERICAN JOURNAL OF PATHOLOGY
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC Activation in Diabetes
- (2012) A. Mima et al. DIABETES
- Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study
- (2012) Flip J.P. Bernink et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms
- (2012) Yochai Birnbaum et al. Metabolic Syndrome and Related Disorders
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
- (2012) Yuji Ishibashi et al. MICROVASCULAR RESEARCH
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
- (2011) John B. Buse et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy
- (2011) Arpita Kalla Vyas et al. PLoS One
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
- (2010) Mark Fineman et al. CLINICAL PHARMACOKINETICS
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
- (2009) Hongbin Liu et al. JOURNAL OF ENDOCRINOLOGY
- GLP-1 Therapy
- (2008) Derek J. Hausenloy et al. Circulation-Heart Failure
- Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
- (2008) Indu Poornima et al. Circulation-Heart Failure
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now